{"doi":"10.1016/j.omtn.2023.07.028","title":"Selection of a novel cell-internalizing RNA aptamer specific for CD22 antigen in B cell acute lymphoblastic leukemia","abstract":"Despite improvements in B cell acute lymphoblastic leukemia (B-ALL) treatment, a significant number of patients experience relapse of the disease, resulting in poor prognosis and high mortality. One of the drawbacks of current B-ALL treatments is the high toxicity associated with the non-specificity of chemotherapeutic drugs. Targeted therapy is an appealing strategy to treat B-ALL to mitigate these toxic off-target effects. One such target is the B cell surface protein CD22. The restricted expression of CD22 on the B-cell lineage and its ligand-induced internalizing properties make it an attractive target in cases of B cell malignancies. To target B-ALL and the CD22 protein, we performed cell internalization SELEX (Systematic Evolution of Ligands by EXponential enrichment) followed by molecular docking to identify internalizing aptamers specific for B-ALL cells that bind the CD22 cell-surface receptor. We identified two RNA aptamers, B-ALL1 and B-ALL2, that target human malignant B cells, with B-ALL1 the first documented RNA aptamer interacting with the CD22 antigen. These B-ALL-specific aptamers represent an important first step toward developing novel targeted therapies for B cell malignancy treatments.","journal":"Molecular Therapy — Nucleic Acids","year":2023,"id":349863,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":10,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9486,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1093396,"name":"Li‐Hsien Lin","orcid":"0000-0002-9120-4193","position":1,"is_corresponding":false},{"id":437801,"name":"Suresh Veeramani","orcid":"0000-0001-9217-0872","position":2,"is_corresponding":false},{"id":1093804,"name":"Maya N. Barros","orcid":null,"position":3,"is_corresponding":false},{"id":1093805,"name":"Diego Sanchez","orcid":null,"position":4,"is_corresponding":false},{"id":1093397,"name":"Ary Lautaro Di Bartolo","orcid":"0000-0002-1314-5714","position":5,"is_corresponding":false},{"id":1093398,"name":"Diego Masone","orcid":"0000-0001-5770-8614","position":6,"is_corresponding":false},{"id":315108,"name":"Paloma H. Giangrande","orcid":"0000-0002-6559-3308","position":7,"is_corresponding":false},{"id":1093806,"name":"María Belén Mestre","orcid":null,"position":8,"is_corresponding":false},{"id":1093399,"name":"William H. Thiel","orcid":"0000-0002-2372-2925","position":9,"is_corresponding":false},{"id":1093395,"name":"Dario Ruiz-Ciancio","orcid":"0000-0002-5039-9588","position":0,"is_corresponding":true}],"reference_count":114,"raw_metadata":null,"created_at":"2026-07-19T01:12:19.059218Z","pmid":"37662970","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}